CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:CTSO
- CUSIP: N/A
- Web: www.cytosorbents.com
Capitalization:- Market Cap: $136.45 million
- Outstanding Shares: 28,133,000
Average Prices:- 50 Day Moving Avg: $4.81
- 200 Day Moving Avg: $4.80
- 52 Week Range: $3.30 - $6.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.32
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $12.18 million
- Price / Sales: 11.20
- Book Value: $0.28 per share
- Price / Book: 17.32
Profitability:- EBIDTA: ($10,410,000.00)
- Net Margins: -80.56%
- Return on Equity: -529.95%
- Return on Assets: -75.38%
Debt:- Debt-to-Equity Ratio: 1.00%
- Current Ratio: 3.17%
- Quick Ratio: 3.03%
Misc:- Average Volume: 107,834 shs.
- Beta: -0.57
- Short Ratio: 11.86
Frequently Asked Questions for Cytosorbents Corporation (NASDAQ:CTSO)
What is Cytosorbents Corporation's stock symbol?
Cytosorbents Corporation trades on the NASDAQ under the ticker symbol "CTSO."
How were Cytosorbents Corporation's earnings last quarter?
Cytosorbents Corporation (NASDAQ:CTSO) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. The business earned $3.57 million during the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative net margin of 80.56% and a negative return on equity of 529.95%. View Cytosorbents Corporation's Earnings History.
When will Cytosorbents Corporation make its next earnings announcement?
Where is Cytosorbents Corporation's stock going? Where will Cytosorbents Corporation's stock price be in 2017?
6 brokers have issued 1 year price targets for Cytosorbents Corporation's shares. Their predictions range from $7.00 to $24.00. On average, they expect Cytosorbents Corporation's share price to reach $12.71 in the next twelve months. View Analyst Ratings for Cytosorbents Corporation.
What are analysts saying about Cytosorbents Corporation stock?
Here are some recent quotes from research analysts about Cytosorbents Corporation stock:
- 1. Maxim Group analysts commented, "Recall back in June of 2016 CytoSorbents entered into a Loan and Security Agreement with Western Alliance Bank, securing an initial $5 million, 4-year term loan with the option of another $5M. On June 30, 2017, the Company elected to drawdown the additional $5 million of funding available under the Loan and Security Agreement, bringing its total borrowings under the facility to $10 million." (7/5/2017)
- 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)
Who are some of Cytosorbents Corporation's key competitors?
Some companies that are related to Cytosorbents Corporation include Alliance HealthCare Services (AIQ), Cogentix Medical (CGNT), Viveve Medical (VIVE), Fulgent Genetic (FLGT), IRIDEX Corporation (IRIX), Harvard Bioscience (HBIO), Edap Tms S.A. (EDAP), Digirad Corporation (DRAD), Neovasc (NVCN), Electromed (ELMD), Presbia PLC (LENS), Biolase (BIOL), Luna Innovations Incorporated (LUNA), Invivo Therapeutics Holdings Corp (NVIV), EnteroMedics (ETRM), Advanced Oncotherapy PLC (AVO), Xtant Medical Holdings (XTNT) and Dynatronics Corporation (DYNT).
Who are Cytosorbents Corporation's key executives?
Cytosorbents Corporation's management team includes the folowing people:
- Al Kraus, Chairman of the Board
- Phillip P. Chan M.D., Ph.D., President, Chief Executive Officer, Director
- Kathleen P. Bloch CPA, Chief Financial Officer
- Vincent J. Capponi, Chief Operating Officer
- Eric G. Mortensen, Chief Medical Officer
- Michael G. Bator, Director
- James T. Gunton, Independent Director
- Edward R. Jones M.D., Independent Director
- Alan D. Sobel, Independent Director
Who owns Cytosorbents Corporation stock?
Cytosorbents Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include Skylands Capital LLC (2.11%), Vanguard Group Inc. (1.61%), Advisor Group Inc. (0.19%), California Public Employees Retirement System (0.16%), PNC Financial Services Group Inc. (0.14%) and Northern Trust Corp (0.13%). Company insiders that own Cytosorbents Corporation stock include Al Kraus, Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents Corporation.
Who sold Cytosorbents Corporation stock? Who is selling Cytosorbents Corporation stock?
Who bought Cytosorbents Corporation stock? Who is buying Cytosorbents Corporation stock?
Cytosorbents Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Skylands Capital LLC and PNC Financial Services Group Inc.. Company insiders that have bought Cytosorbents Corporation stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents Corporation.
How do I buy Cytosorbents Corporation stock?
Shares of Cytosorbents Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytosorbents Corporation's stock price today?
One share of Cytosorbents Corporation stock can currently be purchased for approximately $4.85.
MarketBeat Community Rating for Cytosorbents Corporation (NASDAQ CTSO)MarketBeat's community ratings are surveys of what our community members think about Cytosorbents Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Cytosorbents Corporation (NASDAQ:CTSO)Earnings History by Quarter for Cytosorbents Corporation (NASDAQ CTSO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.07) | | | | | N/A |  |
| 8/7/2017 | Q2 2017 | ($0.06) | ($0.04) | $3.29 million | $3.57 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.11) | ($0.05) | $2.99 million | $3.11 million | View | Listen | |
| 3/3/2017 | Q4 2016 | ($0.10) | ($0.16) | $2.59 million | $3.08 million | View | N/A | |
| 11/7/2016 | Q3 | ($0.11) | ($0.11) | $2.35 million | $2.14 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.09) | ($0.12) | $2.18 million | $1.90 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.10) | ($0.08) | $1.73 million | $1.80 million | View | N/A | |
| 3/9/2016 | Q415 | ($0.08) | ($0.08) | $1.51 million | $1.76 million | View | N/A | |
| 11/13/2015 | Q315 | ($0.10) | ($0.11) | $1.26 million | $1.30 million | View | Listen | |
| 8/13/2015 | Q215 | ($0.11) | $0.05 | $0.92 million | $0.96 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.13) | ($0.11) | $0.80 million | $0.72 million | View | Listen | |
| 8/12/2014 | Q2 2014 | ($0.01) | ($0.01) | $1.13 million | $1.03 million | View | N/A | |
| 3/31/2014 | Q4 2013 | ($0.01) | ($0.01) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cytosorbents Corporation (NASDAQ:CTSO)2017 EPS Consensus Estimate: ($0.34)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.11) | ($0.11) | ($0.11) |
| Q2 2017 | 2 | ($0.07) | ($0.06) | ($0.07) |
| Q3 2017 | 2 | ($0.08) | ($0.07) | ($0.08) |
| Q4 2017 | 2 | ($0.09) | ($0.08) | ($0.09) |
(Data provided by Zacks Investment Research)
Dividend History for Cytosorbents Corporation (NASDAQ:CTSO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cytosorbents Corporation (NASDAQ:CTSO)Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 9.63%
Insider Trades by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/9/2017 | Eric R Mortensen | Insider | Buy | 2,500 | $4.04 | $10,100.00 | |
| 6/9/2017 | Michael G. Bator | Director | Buy | 1,500 | $4.12 | $6,180.00 | |
| 6/8/2017 | Phillip P. Chan | Insider | Buy | 3,700 | $4.00 | $14,800.00 | |
| 6/8/2017 | Vincent Capponi | COO | Buy | 2,500 | $4.00 | $10,000.00 | |
| 6/5/2017 | Phillip P. Chan | Insider | Buy | 6,300 | $4.00 | $25,200.00 | |
| 5/15/2017 | Kathleen P. Bloch | CFO | Buy | 1,000 | $4.34 | $4,340.00 | |
| 12/9/2016 | Phillip P. Chan | Insider | Buy | 4,600 | $5.40 | $24,840.00 | |
| 12/6/2016 | Kathleen P Bloch | CFO | Buy | 1,000 | $4.83 | $4,830.00 | |
| 8/24/2016 | Phillip P Chan | Insider | Buy | 5,000 | $4.89 | $24,450.00 | |
| 6/7/2016 | Michael G Bator | Director | Buy | 3,000 | $4.88 | $14,640.00 | |
| 10/29/2015 | Vincent Capponi | COO | Sell | 4,000 | $7.50 | $30,000.00 | |
| 10/15/2015 | Al Kraus | Director | Sell | 6,774 | $6.22 | $42,134.28 | |
| 10/8/2015 | Al Kraus | Director | Sell | 10,000 | $6.39 | $63,900.00 | |
| 10/1/2015 | Al Kraus | Director | Sell | 10,000 | $6.26 | $62,600.00 | |
| 9/24/2015 | Al Kraus | Director | Sell | 10,000 | $6.44 | $64,400.00 | |
| 9/17/2015 | Al Kraus | Director | Sell | 10,000 | $6.64 | $66,400.00 | |
| 9/10/2015 | Al Kraus | Director | Sell | 10,000 | $7.26 | $72,600.00 | |
| 9/3/2015 | Al Kraus | Director | Sell | 10,000 | $7.26 | $72,600.00 | |
| 8/27/2015 | Al Kraus | Director | Sell | 10,000 | $6.39 | $63,900.00 | |
| 8/20/2015 | Al Kraus | Director | Sell | 10,000 | $7.26 | $72,600.00 | |
| 8/13/2015 | Al Kraus | Director | Sell | 10,000 | $6.26 | $62,600.00 | |
| 7/23/2015 | Al Kraus | Director | Sell | 10,000 | $6.28 | $62,800.00 | |
| 7/16/2015 | Al Kraus | Director | Sell | 10,000 | $6.33 | $63,300.00 | |
| 7/9/2015 | Al Kraus | Director | Sell | 10,000 | $5.98 | $59,800.00 | |
| 7/2/2015 | Al Kraus | Director | Sell | 10,000 | $6.29 | $62,900.00 | |
| 6/25/2015 | Al Kraus | Director | Sell | 13,205 | $7.33 | $96,792.65 | |
| 6/18/2015 | Al Kraus | Director | Sell | 10,000 | $5.78 | $57,800.00 | |
| 6/11/2015 | Al Kraus | Director | Sell | 10,000 | $6.29 | $62,900.00 | |
| 6/4/2015 | Al Kraus | Director | Sell | 10,000 | $6.30 | $63,000.00 | |
| 5/28/2015 | Al Kraus | Director | Sell | 10,000 | $6.32 | $63,200.00 | |
| 11/17/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 11/10/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 11/3/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 10/27/2014 | Al Kraus | Director | Sell | 100,000 | $0.24 | $24,000.00 | |
| 10/10/2014 | James T Gunton | Director | Sell | 1,240,762 | $0.24 | $297,782.88 | |
| 10/6/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 9/29/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 9/25/2014 | Al Kraus | Director | Sell | 41,500 | $0.23 | $9,545.00 | |
| 9/22/2014 | Al Kraus | Director | Sell | 8,500 | $0.23 | $1,955.00 | |
| 9/15/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 9/12/2014 | James T Gunton | Director | Sell | 30,450 | $0.24 | $7,308.00 | |
| 9/8/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 9/5/2014 | James T Gunton | Director | Sell | 100,000 | $0.24 | $24,000.00 | |
| 9/2/2014 | Al Kraus | Director | Sell | 50,000 | $0.25 | $12,500.00 | |
| 9/2/2014 | Kathleen P Bloch | CFO | Buy | 65,000 | $0.23 | $14,950.00 | |
| 8/28/2014 | James T Gunton | Director | Sell | 214,387 | $0.24 | $51,452.88 | |
| 8/27/2014 | James T Gunton | Director | Sell | 1,360,000 | $0.24 | $326,400.00 | |
| 8/25/2014 | Al Kraus | Director | Sell | 100,000 | $0.25 | $25,000.00 | |
| 8/18/2014 | Al Kraus | Director | Sell | 100,000 | $0.27 | $27,000.00 | |
| 8/11/2014 | Al Kraus | Director | Sell | 100,000 | $0.28 | $28,000.00 | |
| 8/4/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | |
| 7/21/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | |
| 7/10/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | |
| 7/7/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | |
| 6/23/2014 | Al Kraus | Director | Sell | 50,000 | $0.23 | $11,500.00 | |
| 6/18/2014 | Al Kraus | Director | Sell | 50,000 | $0.24 | $12,000.00 | |
| 5/20/2014 | Kathleen P Bloch | CFO | Buy | 110,000 | $0.24 | $26,400.00 | |
| 9/4/2012 | Phillip P Chan | CEO | Buy | 190,000 | $0.13 | $24,700.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cytosorbents Corporation (NASDAQ:CTSO)
Latest Headlines for Cytosorbents Corporation (NASDAQ:CTSO)
| Source: |
|
| Date | Headline |
|---|
 | Cytosorbents Corporation (CTSO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 23 at 3:32 AM |
| Analysts Expect Cytosorbents Corporation (CTSO) Will Post Quarterly Sales of $3.67 Million
www.americanbankingnews.com - August 20 at 3:32 AM |
| Cytosorbents Corporation (CTSO) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - August 18 at 6:12 PM |
 | Cytosorbents (CTSO) Secures $719K Grant to Acutely Stabilize Severe Burn Patients
www.streetinsider.com - August 16 at 6:03 PM |
| Cytosorbents (CTSO) Secures $719K Grant to Acutely Stabilize Severe Burn Patients - StreetInsider.com
www.streetinsider.com - August 14 at 5:59 PM |
 | CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients
finance.yahoo.com - August 14 at 5:59 PM |
| CTSO: Product Revenue Sets New Record, Further Growth Expected in 2H
finance.yahoo.com - August 14 at 5:59 PM |
| B. Riley Reaffirms Buy Rating for Cytosorbents Corporation (NASDAQ:CTSO)
www.americanbankingnews.com - August 12 at 5:08 PM |
 | CytoSorbents' (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 5:21 PM |
 | CytoSorbents reports 2Q loss
www.cnbc.com - August 8 at 4:05 AM |
| Cytosorbents Corporation (CTSO) Receives "Buy" Rating from B. Riley
www.americanbankingnews.com - August 7 at 8:38 PM |
| Cytosorbents Corporation (CTSO) Releases Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 7 at 8:08 PM |
 | CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 - PR Newswire (press release)
www.prnewswire.com - August 7 at 6:02 PM |
| CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017
finance.yahoo.com - August 7 at 6:02 PM |
| Cytosorbents Corporation (CTSO) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 3 at 10:40 AM |
| Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
finance.yahoo.com - August 2 at 6:28 PM |
| Brokerages Expect Cytosorbents Corporation (NASDAQ:CTSO) Will Announce Quarterly Sales of $3.29 Million
www.americanbankingnews.com - August 2 at 8:30 AM |
| CytoSorbents to Report Q2 2017 Operating and Financial Results
finance.yahoo.com - August 1 at 6:20 PM |
| Cytosorbents Corporation (CTSO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 29 at 7:26 AM |
| Cytosorbents Corporation's (CTSO) Buy Rating Reiterated at Aegis
www.americanbankingnews.com - July 25 at 2:44 PM |
| CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR - PR Newswire (press release)
www.prnewswire.com - July 17 at 5:56 PM |
| CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR
finance.yahoo.com - July 17 at 12:12 PM |
| CytoSorbents Awarded $1 Million STTR Phase II Contract To ... - PR Newswire (press release)
www.prnewswire.com - July 14 at 4:52 AM |
| Cytosorbents (CTSO) Secures $1M STTR Phase II Contract To ... - StreetInsider.com
www.streetinsider.com - July 13 at 6:51 PM |
| $3.29 Million in Sales Expected for Cytosorbents Corporation (CTSO) This Quarter
www.americanbankingnews.com - July 9 at 10:00 AM |
| Zacks: Brokerages Anticipate Cytosorbents Corporation (CTSO) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - July 7 at 8:55 AM |
| CytoSorbents receives additional $5M in non-dilutive debt financing from Bridge Bank
seekingalpha.com - July 5 at 6:24 PM |
| Cytosorbents Corporation (NASDAQ:CTSO) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - July 5 at 1:58 PM |
| Cytosorbents Corporation (CTSO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 4 at 12:32 AM |
| Cytosorbents: A Razor & Razor Blade Story
seekingalpha.com - June 28 at 5:31 PM |
| CytoSorbents Announces Director and Management Open Market Stock Purchases
finance.yahoo.com - June 15 at 6:30 PM |
| Cytosorbents Corporation (CTSO) Expected to Post Quarterly Sales of $3.29 Million
www.americanbankingnews.com - June 15 at 11:54 AM |
| ABIOMED (ABMD) and Cytosorbents Corporation (CTSO) Critical Survey
www.americanbankingnews.com - June 14 at 7:50 AM |
| Insider Buying: Cytosorbents Corporation (CTSO) Insider Buys 2,500 Shares of Stock
www.americanbankingnews.com - June 13 at 9:02 PM |
| -$0.06 Earnings Per Share Expected for Cytosorbents Corporation (CTSO) This Quarter
www.americanbankingnews.com - June 13 at 8:20 AM |
| Insider Buying: Cytosorbents Corp (CTSO) Insider Purchases 3,700 Shares of Stock
www.americanbankingnews.com - June 8 at 8:20 PM |
| Cytosorbents Corp (CTSO) Now Covered by Analysts at Cowen and Company
www.americanbankingnews.com - June 7 at 8:32 PM |
| Cytosorbents Corp (CTSO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 7 at 8:34 AM |
| Cytosorbents Corp (CTSO) Insider Phillip P. Chan Buys 6,300 Shares
www.americanbankingnews.com - June 6 at 8:41 PM |
| CytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors
finance.yahoo.com - June 6 at 4:48 PM |
| Cytosorbents Corp (CTSO) & ABIOMED (ABMD) Critical Comparison
www.americanbankingnews.com - June 6 at 8:44 AM |
| Cytosorbents (CTSO) Names Dr. Eric G. Mortensen as Chief Medical ... - StreetInsider.com
www.streetinsider.com - May 30 at 9:55 PM |
| Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer
finance.yahoo.com - May 30 at 11:51 AM |
| CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference
finance.yahoo.com - May 24 at 12:40 PM |
| Cytosorbents Corp (CTSO) PT Set at $10.00 by Maxim Group
www.americanbankingnews.com - May 23 at 8:04 PM |
| ETFs with exposure to CytoSorbents Corp. : May 22, 2017
finance.yahoo.com - May 22 at 4:22 PM |
| Aferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021
finance.yahoo.com - May 22 at 12:16 PM |
| Cytosorbents Corp (CTSO) to Post Q2 2017 Earnings of ($0.07) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - May 17 at 8:00 AM |
| Zacks: Analysts Expect Cytosorbents Corp (CTSO) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - May 16 at 4:04 PM |
| Research Analysts Issue Forecasts for Cytosorbents Corp's FY2020 Earnings (CTSO)
www.americanbankingnews.com - May 16 at 1:48 PM |
Cytosorbents Corporation (CTSO) Chart for Thursday, August, 24, 2017
